Publications & Posters
Diagnostics | October 18, 2016
Tanya Bogoslovsky, Jessica Gill, Andreas Jeromin, Cora Davis and Ramon Diaz-Arrastia Diagnostics DOI: 10.3390/diagnostics6040037 Download Paper
A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics
Alzheimer's Research & Therapy | December 15, 2016
The digital ELISA developed in this study provided sensitive and precise measurement of plasma Aβ1–42 in clinical samples treated with the BACE1 inhibitor LY2886721. The improved assay sensitivity enabled Aβ1–42 to be reliably quantified even at low picogram-per-milliliter levels.
Neurology | February 8, 2017
To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders.
JAMA Neurology | March 27, 2017
Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias.
Current AIDS/HIV Report | April 11, 2017
The development and evaluation of strategies for HIV remission rely upon our ability to accurately and precisely quantify the size of the remaining viral reservoir.
Journal of Alzheimer's Disease| May 25, 2017
Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.